Stockscreener 앱 받기
1.46
5.04%
0.07
전일 마감가:
$1.39
열려 있는:
$1.41
하루 거래량:
354.93K
Relative Volume:
0.72
시가총액:
$153.80M
수익:
$7.05M
순이익/손실:
$-30.43M
주가수익비율:
-3.8543
EPS:
-0.3788
순현금흐름:
$21.84M
1주 성능:
-2.67%
1개월 성능:
-10.98%
6개월 성능:
-27.72%
1년 성능:
-35.68%
1일 변동 폭
$1.41
$1.54
1주일 범위
$1.33
$1.5528
52주 변동 폭
$1.07
$3.10
Proqr Therapeutics N V Stock (PRQR) Company Profile
Compare PRQR vs VRTX, REGN, ARGX, ALNY, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
PRQR
Proqr Therapeutics N V
|
1.46 | 146.43M | 7.05M | -30.43M | 21.84M | -0.3788 |
|
VRTX
Vertex Pharmaceuticals Inc
|
491.47 | 117.98B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
803.17 | 82.85B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
821.96 | 51.58B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
314.40 | 40.75B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
346.07 | 38.33B | 4.98B | 69.60M | 525.67M | 0.5198 |
Proqr Therapeutics N V Stock (PRQR) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-04-29 | 재개 | Cantor Fitzgerald | Overweight |
| 2025-04-29 | 개시 | Evercore ISI | Outperform |
| 2025-03-10 | 업그레이드 | Citigroup | Neutral → Buy |
| 2025-01-10 | 개시 | Oppenheimer | Outperform |
| 2024-10-29 | 업그레이드 | Raymond James | Outperform → Strong Buy |
| 2023-11-08 | 업그레이드 | Chardan Capital Markets | Neutral → Buy |
| 2023-03-30 | 업그레이드 | JMP Securities | Mkt Perform → Mkt Outperform |
| 2022-12-22 | 업그레이드 | Cantor Fitzgerald | Neutral → Overweight |
| 2022-02-14 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2022-02-11 | 다운그레이드 | Raymond James | Strong Buy → Mkt Perform |
| 2022-02-11 | 다운그레이드 | Stifel | Buy → Hold |
| 2022-02-01 | 개시 | Raymond James | Strong Buy |
| 2021-05-03 | 개시 | Stifel | Buy |
| 2021-03-25 | 재확인 | Citigroup | Buy |
| 2020-11-03 | 재개 | Cantor Fitzgerald | Overweight |
| 2019-03-12 | 재확인 | Chardan Capital Markets | Buy |
| 2018-12-19 | 개시 | RBC Capital Mkts | Outperform |
| 2018-11-15 | 개시 | Citigroup | Buy |
| 2018-09-19 | 개시 | Evercore ISI | Outperform |
| 2017-09-26 | 재확인 | JMP Securities | Mkt Outperform |
| 2016-06-20 | 개시 | Chardan Capital Markets | Neutral |
| 2014-10-15 | 개시 | Deutsche Bank | Buy |
| 2014-10-13 | 개시 | H.C. Wainwright | Buy |
모두보기
Proqr Therapeutics N V 주식(PRQR)의 최신 뉴스
ProQR Therapeutics N.V. (NASDAQ:PRQR) Short Interest Up 47.2% in January - MarketBeat
Can ProQR Therapeutics N.V. withstand a market correctionCPI Data & Community Verified Watchlist Alerts - mfd.ru
Is ProQR Therapeutics N.V. currently under institutional pressureChart Signals & Long-Term Growth Portfolio Plans - mfd.ru
Will ProQR Therapeutics N.V. stock recover after earningsPortfolio Gains Summary & Weekly High Conviction Trade Ideas - mfd.ru
A | Is ProQR Therapeutics N.V. stock showing strong momentumJuly 2025 Levels & Risk Controlled Swing Alerts - mfd.ru
Aug Levels: Is ProQR Therapeutics NV stock a buy or sellJuly 2025 Institutional & Reliable Price Breakout Alerts - baoquankhu1.vn
ProQR Therapeutics N.V. (NASDAQ:PRQR) Receives Average Recommendation of "Moderate Buy" from Analysts - MarketBeat
ProQR announces board changes as two members set to depart By Investing.com - Investing.com South Africa
ProQR announces board changes as two members set to depart - Investing.com
ProQR Therapeutics (PRQR) Announces Board Changes at Upcoming AG - GuruFocus
ProQR Announces Planned Changes to Board Composition - markets.businessinsider.com
ProQR Therapeutics Plans Board Changes as Co-Founder and Director Exit at 2026 AGM - TipRanks
Co-founder among 2 ProQR directors set to leave board at 2026 AGM - Stock Titan
ProQR Therapeutics NV Announces Departure of Board Members Dinko Valerio and Alison Lawton - Longbridge
Myriad Genetics (NASDAQ:MYGN) & ProQR Therapeutics (NASDAQ:PRQR) Head-To-Head Survey - Defense World
ProQR Aktie: Pipeline-Fortschritte - Börse Global
Risk Recap: Will ProQR Therapeutics NV stock recover after earningsJuly 2025 Highlights & Capital Efficient Trading Techniques - baoquankhu1.vn
Dip Buying: Is Sharps Technology Inc Equity Warrant in a bullish channelWeekly Market Report & Free Risk Controlled Daily Trade Plans - baoquankhu1.vn
Gains Recap: Is ProQR Therapeutics NV a cyclical or defensive stockEarnings Trend Report & AI Powered Trade Plan Recommendations - baoquankhu1.vn
Quarterly Earnings: Can ProQR Therapeutics NV weather a recessionWeekly Stock Recap & Daily Entry Point Trade Alerts - baoquankhu1.vn
ProQR Therapeutics N.V. (NASDAQ:PRQR) Not Doing Enough For Some Investors As Its Shares Slump 28% - 富途牛牛
Aug PreEarnings: Is KFFB stock undervalued right nowTrade Entry Report & Weekly Stock Performance Updates - baoquankhu1.vn
Market Recap: Can SBEV be recession proofQuarterly Trade Report & Free Community Consensus Stock Picks - baoquankhu1.vn
Obesity Market on Track for Major Expansion by 2034, According to DelveInsight | Rhythm Pharmaceuticals, Boehringer Ingelheim, D&D Pharmatech, ProQR Therapeutics, Nano Precision Medical, Bukwang Pharm - Barchart.com
Earnings Miss: Can ProQR Therapeutics NV reach resistance levels soon2025 AllTime Highs & Expert Verified Movement Alerts - baoquankhu1.vn
Trading Recap: Is Alumis Inc gaining market shareJuly 2025 Market Mood & Growth Focused Entry Point Reports - baoquankhu1.vn
Day Trade: Does OLMA have strong EBITDA marginsJuly 2025 Volume & Weekly Watchlist for Hot Stocks - baoquankhu1.vn
Published on: 2026-01-18 21:01:57 - baoquankhu1.vn
ProQR Therapeutics N.V. (NASDAQ:PRQR) Receives Consensus Rating of "Moderate Buy" from Brokerages - MarketBeat
ProQR Therapeutics N.V. (NASDAQ:PRQR) Receives Consensus Rating of “Moderate Buy” from Brokerages - Defense World
Aug Patterns: What insider trading reveals about ProQR Therapeutics NV stockProfit Target & Consistent Growth Equity Picks - Bộ Nội Vụ
Why Investors Shouldn't Be Surprised By ProQR Therapeutics N.V.'s (NASDAQ:PRQR) 28% Share Price Plunge - simplywall.st
Working capital per share of ProQR Therapeutics N.V. – FWB:0PQ - TradingView — Track All Markets
ProQR reports positive initial AX-0810 safety data in phase 1 trial - Investing.com Nigeria
Will ProQR Therapeutics N.V. stock deliver long term returnsDip Buying & Free Community Consensus Stock Picks - ulpravda.ru
ProQR stock falls after initial AX-0810 data, pipeline updates By Investing.com - Investing.com Australia
Why ProQR Therapeutics N.V. (0PQ) stock stays undervalued2025 Price Momentum & Weekly Stock Breakout Alerts - ulpravda.ru
Why ProQR Therapeutics N.V. stock is a value investor pick2025 Pullback Review & Risk Adjusted Swing Trade Ideas - Улправда
ProQR stock falls after initial AX-0810 data, pipeline updates - Investing.com
ProQR announces encouraging AX-0810 phase 1 - MarketScreener
ProQR Reports Positive AX-0810 Phase 1 Data, Advances Rett and MASH Candidates, and Outlines 2026 Pipeline Plans - TipRanks
ProQR reports positive initial AX-0810 safety data in phase 1 trial By Investing.com - Investing.com South Africa
ProQR (PRQR) details encouraging AX-0810 Phase 1 data and 2026 plans - Stock Titan
ProQR Announces Encouraging AX-0810 Phase 1 Safety and PK - GlobeNewswire
ProQR Therapeutics (NASDAQ:PRQR) Share Price Passes Below 50 Day Moving AverageHere's What Happened - MarketBeat
Why ProQR Therapeutics N.V. stock is considered a top pickCapital Gains Strategies & Create Passive Income With Smart Stocks - ulpravda.ru
ProQR Therapeutics N.V. (PRQR) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
ProQR Therapeutics (NASDAQ:PRQR) Stock Crosses Below 50-Day Moving AverageHere's What Happened - MarketBeat
ProQR Therapeutics N.V.'s (NASDAQ:PRQR) top owners are individual investors with 34% stake, while 29% is held by institutions - Yahoo Finance
ProQR Therapeutics N.V. (NASDAQ:PRQR) Receives Consensus Recommendation of “Moderate Buy” from Analysts - Defense World
ProQR Therapeutics N.V. (NASDAQ:PRQR) Receives Consensus Recommendation of "Moderate Buy" from Analysts - MarketBeat
Proqr Therapeutics N V (PRQR) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.12%
0.87%
자본화:
|
볼륨(24시간):